We spoke to Kris Sterkens, Janssen’s company group chairman EMEA, about the challenges facing big pharma and the increasing importance of engaging with patients
Alexander Gray and Mike Rea from IDEA Pharma explain why the current pharma R&D model is broken, and how it’s hindering commercialisation across the industry
Doug Danison from bluebird bio on the obstacles, opportunities and required change in thinking needed to ensure patients have access to innovative personalised medicines